ImmunityBio Inc. [NASDAQ: IBRX] closed the trading session at $22.40 on 04/01/21. The day’s price range saw the stock hit a low of $21.89, while the highest price level was $23.95. The company report on April 1, 2021 that ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard Adcock to the board; he was named CEO of NantKwest in October and remains the CEO of the company after the merger of NantKwest with ImmunityBio in March. Both appointments are effective March 29, 2021.
The nine-member ImmunityBio board is led by Founder and Executive Chairman Patrick Soon-Shiong, M.D. The board includes two other recently appointed outside members, former CIA director John Brennan and retired U.S. Army General Wesley Clark, along with current board members Michael Blaszyk, Cheryl Cohen, Christobel Selecky, and Barry Simon, M.D.
The stocks have a year to date performance of 68.04 percent and weekly performance of -27.48 percent. The stock has been moved at 223.00 percent over the last six months. The stock has performed -15.73 percent around the most recent 30 days and changed 55.99 percent over the most recent 3-months.
If compared to the average trading volume of 1.50M shares, IBRX reached to a volume of 1221696 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ImmunityBio Inc. [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $18.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for ImmunityBio Inc. is set at 4.01, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 90966.40. The Price to Book ratio for the last quarter was 20.74, with the Price to Cash per share for the same quarter was set at 0.16.
IBRX stock trade performance evaluation
ImmunityBio Inc. [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -27.48. With this latest performance, IBRX shares dropped by -15.73% in over the last four-week period, additionally plugging by 223.00% over the last 6 months – not to mention a rise of 723.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 38.46, with the RSI for the last a single of trading hit 31.64, and the three-weeks RSI is set at 42.81 for ImmunityBio Inc. [IBRX]. The present Moving Average for the last 50 days of trading for this stock 28.40, while it was recorded at 24.27 for the last single week of trading, and 14.81 for the last 200 days.
ImmunityBio Inc. [IBRX]: An insightful look at the core fundamentals
ImmunityBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.10.
Earnings per share (EPS) analysis for ImmunityBio Inc. [IBRX] stock
With the latest financial reports released by the company, ImmunityBio Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc. go to -1.70%.
ImmunityBio Inc. [IBRX]: Insider Ownership positions
There are presently around $262 million, or 3.10% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: BLACKROCK INC. with ownership of 3,303,410, which is approximately 56.809% of the company’s market cap and around 8.60% of the total institutional ownership; VANGUARD GROUP INC, holding 2,027,882 shares of the stock with an approximate value of $45.42 million in IBRX stocks shares; and STATE STREET CORP, currently with $14.94 million in IBRX stock with ownership of nearly 25.097% of the company’s market capitalization.
63 institutional holders increased their position in ImmunityBio Inc. [NASDAQ:IBRX] by around 3,659,571 shares. Additionally, 45 investors decreased positions by around 2,163,726 shares, while 17 investors held positions by with 5,858,536 shares. The mentioned changes placed institutional holdings at 11,681,833 shares, according to the latest SEC report filing. IBRX stock had 31 new institutional investments in for a total of 1,052,830 shares, while 21 institutional investors sold positions of 1,883,900 shares during the same period.